The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: Lumira Capital

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio:

Biotech Trends Update — Commercialization by Foundations: $500k to AVI BioPharma from DMD Organizations

Continuing a trend by nonprofits to invest directly in commercialization of relevant products, CureDuchenne and the Foundation to Eradicate Duchenne each awarded grants of $250,000 to AVI BioPharma, Inc. (NASDAQ: AVII) to support continued research and development of the Company’s drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD).

One interesting note here is the collaboration between foundations, something we also saw in an ALS project in December.   This is a great way for smaller foundations to maximize their impact on the (expensive!) drug development process.

Both foundations, run by parents of kids with DMD, are focused on commercial products:

“CureDuchenne is very happy to support AVI BioPharma as it advances these treatments to boys with DMD as soon as possible.”

“The exon-skipping strategies being developed by AVI offer the greatest prospect for meaningful clinical therapies.”

Bookmark and Share

Canadian Life Sciences VCs Lead the Realization Parade

Liquidity Shrivels Up For VCs in First Quarter” was the banner screaming across the wire services earlier this week. While true, what was lost in the subtext were a few important observations for Canadian VCs, particularly those focused on life sciences:

Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 131 other followers